These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15977912)

  • 21. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
    Yu YF; Nichol MB; Yu AP; Ahn J
    Value Health; 2005; 8(4):495-505. PubMed ID: 16091027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
    Sura S; Shiozawa A; Ng D; Aparasu RR
    J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economic burden of overactive bladder in the United States: A systematic literature review.
    Powell LC; Szabo SM; Walker D; Gooch K
    Neurourol Urodyn; 2018 Apr; 37(4):1241-1249. PubMed ID: 29331047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Employees with overactive bladder: work loss burden.
    Wu EQ; Birnbaum H; Marynchenko M; Mareva M; Williamson T; Mallett D
    J Occup Environ Med; 2005 May; 47(5):439-46. PubMed ID: 15891521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower urinary tract symptoms in women.
    Milsom I
    Curr Opin Urol; 2009 Jul; 19(4):337-41. PubMed ID: 19444118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.
    Jimenez-Cidre M; Costa P; Ng-Mak D; Sahai A; Degboe A; Smith CP; Tsai K; Herschorn S
    Curr Med Res Opin; 2014 Aug; 30(8):1557-64. PubMed ID: 24762033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related consequences of overactive bladder: an economic perspective.
    Hu TW; Wagner TH
    BJU Int; 2005 Sep; 96 Suppl 1():43-5. PubMed ID: 16086679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comorbidities associated with overactive bladder.
    Brown JS; McGhan WF; Chokroverty S
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S574-9. PubMed ID: 11183900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study.
    Balkrishnan R; Bhosle MJ; Camacho FT; Anderson RT
    J Urol; 2006 Mar; 175(3 Pt 1):1067-71; discussion 1071-2. PubMed ID: 16469620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
    Hu TW; Wagner TH; Bentkover JD; Leblanc K; Zhou SZ; Hunt T
    Urology; 2004 Mar; 63(3):461-5. PubMed ID: 15028438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage.
    Cisternas MG; Foreman AJ; Marshall TS; Runken MC; Kobashi KC; Seifeldin R
    Curr Med Res Opin; 2009 Apr; 25(4):911-9. PubMed ID: 19250059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
    Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
    PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical evaluation of the overactive bladder and urgency urinary incontinence association with obstructive sleep apnea syndrome in a relatively young adult male population.
    Tuncer M; Yazici O; Kafkasli A; Sabuncu K; Salepci B; Narter F; Gungor GA; Yucetas U
    Neurourol Urodyn; 2017 Sep; 36(7):1804-1808. PubMed ID: 27921319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population.
    Lai HH; Shen B; Rawal A; Vetter J
    BMC Urol; 2016 Oct; 16(1):60. PubMed ID: 27716241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Economic impact of overactive bladder symptoms in Japan].
    Inoue S; Kobayashi M; Sugaya K
    Nihon Hinyokika Gakkai Zasshi; 2008 Nov; 99(7):713-22. PubMed ID: 19068687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
    Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
    Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.